Product image of Natriumglycerophosphat-Ampulle Fresenius (Sodium Glycerophosphate Pentahydrate) supplied by GNH India

Natriumglycerophosphat-Ampulle Fresenius

Active Ingredient:
Sodium Glycerophosphate Pentahydrate
Origin:
EU

Natriumglycerophosphat-Ampulle Fresenius (Sodium Glycerophosphate Pentahydrate)

Sodium glycerophosphate pentahydrate, the active ingredient in Natrumglycerophosphat-Ampulle Fresenius, is a phosphate solution presented as an injectable solution for intravenous use. It provides phosphate and sodium ions to correct deficiencies, particularly in patients requiring parenteral nutrition or those with low serum phosphate levels.

GNH India supplies Natrumglycerophosphat-Ampulle Fresenius as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and oncology centres worldwide. The product meets EU quality standards and is packaged for sterile administration.

Manufacturer / TM Owner

Fresenius Kabi Deutschland Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Natrumglycerophosphat is used to manage conditions related to phosphate deficiency and metabolic balance.

  • Hypophosphatemia: restores serum phosphate levels in patients with low phosphate.
  • Parenteral nutrition: supplies essential phosphate as part of total nutrient admixtures.
  • Metabolic alkalosis: acts as a buffering agent to correct acid‑base disturbances.

How It Works

  • After intravenous administration, sodium glycerophosphate pentahydrate dissociates into sodium and glycerophosphate ions. The glycerophosphate component releases inorganic phosphate, which participates in ATP synthesis, cellular signaling, and acid‑base buffering. The sodium component contributes to extracellular fluid volume and osmolarity, supporting electrolyte balance during therapy.

Side Effects

Sodium glycerophosphate may cause a range of adverse reactions, most of which are related to electrolyte shifts or local injection responses.

Common Side Effects

  • Hyperphosphatemia: elevated serum phosphate levels.
  • Hypocalcemia: reduced calcium concentration secondary to phosphate binding.
  • Injection site pain or erythema.
  • Nausea or mild gastrointestinal discomfort.

Serious or Rare Side Effects

  • Calcium‑phosphate precipitation leading to tissue calcification.
  • Severe hypotension or cardiovascular instability.
  • Anaphylactic or severe allergic reaction.
  • Cardiac arrhythmias due to electrolyte imbalance.
  • Exacerbation of renal failure in susceptible patients.

Precautions & Warnings

When using Natrumglycerophosphat, clinicians should observe several safety measures to minimize risks.

  • Serum phosphate monitoring: check levels before and during therapy.
  • Renal function assessment: avoid rapid infusion in severe renal impairment.
  • Calcium compatibility: do not mix with calcium‑containing solutions.
  • Infusion rate: administer over the recommended period to prevent abrupt electrolyte shifts.
  • Pregnancy and lactation: use only if the expected benefit outweighs potential risk.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Sodium glycerophosphate can interact with other agents that affect phosphate balance or form insoluble complexes.

Major Interactions (Avoid)

  • Calcium salts: risk of insoluble calcium‑phosphate precipitation.
  • Magnesium salts: may precipitate and reduce drug efficacy.
  • Aluminum‑containing antacids: can bind phosphate and diminish availability.

Moderate Interactions (Monitor Closely)

  • Loop diuretics: increase urinary phosphate loss, may require dose adjustment.
  • Vitamin D analogues: enhance phosphate absorption, monitor serum levels.
  • ACE inhibitors: may alter renal handling of phosphate, requiring observation.

Frequently Asked Questions

Natrumglycerophosphat contains sodium glycerophosphate pentahydrate and is used intravenously to correct low serum phosphate levels, support phosphate needs during parenteral nutrition, and help manage metabolic alkalosis by providing a buffering phosphate source.

After injection, the compound dissociates into sodium and glycerophosphate ions. The glycerophosphate releases inorganic phosphate, which is essential for ATP production, cellular signaling, and acid‑base balance, while the sodium contributes to extracellular fluid volume and electrolyte homeostasis.

The dose of Natrumglycerophosphat is determined by the prescribing clinician based on the patient’s serum phosphate level, renal function, and overall clinical condition. Healthcare professionals calculate the appropriate amount and infusion rate for each individual case.

Safety in pregnancy and lactation has not been fully established. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Natrumglycerophosphate delivers both phosphate and sodium in a single sterile solution, which can simplify dosing compared with separate sodium and phosphate preparations. It is particularly useful when a rapid correction of phosphate is needed and when compatibility with other intravenous components is considered.

The product should be stored at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the vial in its original packaging until use to maintain sterility and stability.

Natrumglycerophosphat is given as an intravenous injection or infusion. The solution is added to a compatible IV bag or administered directly, following aseptic technique and the infusion rate recommended by the prescribing clinician.

Serious risks include severe hyperphosphatemia leading to calcium‑phosphate precipitation, which can cause tissue calcification, as well as anaphylactic reactions, marked hypotension, and cardiac arrhythmias. Monitoring serum electrolytes and patient response is essential to mitigate these risks.

Patients with known hypersensitivity to sodium glycerophosphate, uncontrolled hyperphosphatemia, severe renal failure where rapid phosphate loading is contraindicated, or those receiving incompatible calcium‑containing IV solutions should not be given Natrumglycerophosphat.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Sodium Glycerophosphate Pentahydrate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT